







# Differentiation of sphingomyelin and cholesterol by hyperspectral mid-infrared detection of single-bond vibrational modes in the fingerprint region

Received: 11 February 2025

Accepted: 5 February 2026

Published online: 30 March 2026

 Check for updates

Francesca Gasparin <sup>1,2</sup>, Alexander Prebeck <sup>1,2</sup>, Alice Soldà<sup>1,2</sup>, Nasire Uluç<sup>1,2,3</sup>, Sarah Glasl<sup>1,2</sup>, Constantin Berger <sup>1,2,4</sup>, Miguel A. Pleitez <sup>1,2</sup> & Vasilis Ntziachristos <sup>1,2,5</sup> 

Lipids play a central role in a multitude of biological functions associated with cancer, obesity, diabetes, cardiovascular and neurological pathologies. However, sensing and mapping of lipid classes in living cells remains challenging. Here we introduce a label-free approach to lipid imaging, which differentiates lipid species in living cells by hyperspectral mid-infrared detection of single-bond vibrational modes within the fingerprint region. Hyperspectral fingerprint optoacoustic microscopy is shown to resolve phosphatidylcholine, sphingomyelin or cholesterol in test samples and in synthetic giant unilamellar vesicles used as models of cell membranes. Then, mapping of total cholesterol and sphingomyelin content and accumulation dynamics are demonstrated in living cells. Hyperspectral fingerprint optoacoustic microscopy demonstrates sensitivity not only in discerning lipids with substantially different chemical structures, such as cholesterol and phospholipids, but also lipids that are chemically similar, such as sphingomyelins and glycerophospholipids.

Besides being used as energy storage and structural cell membrane elements, lipids are implicated in multiple pathways of tissue function or disease progression. With an increasing understanding of the diversity of these roles, there is growing research to elucidate the implications of lipids in cancer, obesity, diabetes, neurological or cardiovascular diseases. Lipidomics and genome-wide association studies have revealed diverse disease-associated defects in lipid pathways; however, the need for observations of specific lipid species in living systems is necessary to better decipher dynamic relations between lipid metabolism, disease evolution and the effect of environmental and lifestyle influences<sup>1</sup>.

Optical microscopy methods, such as photo-activated localization microscopy, has used plasmid-encoded fluorescent toxins and proteins for targeting cholesterol (Chol) and sphingomyelin (SM)-enriched microdomains<sup>2,3</sup>. Fluorescence resonance energy transfer, stochastic optical reconstruction microscopy<sup>4</sup> and stimulated emission depletion microscopy<sup>5</sup> have also shown spatiotemporal observations of lipid species. Nevertheless, lipid staining may be limited by the efficiency of delivering a label into the living cells, the selectivity and specificity of the label to specific lipids or lipid classes, the ability to multiplex concurrent targeting of multiple lipid species and the possible

<sup>1</sup>Chair of Biological Imaging, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health & School of Computation, Information and Technology, Technical University of Munich, Munich, Germany. <sup>2</sup>Institute of Biological and Medical Imaging, Bioengineering Center, Helmholtz Zentrum München, Neuherberg, Germany. <sup>3</sup>Department of Physics, Middle East Technical University, Ankara, Turkey. <sup>4</sup>Institute of Computational Biology, Bioengineering Center, Helmholtz Zentrum München, Neuherberg, Germany. <sup>5</sup>DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. ✉e-mail: [bioimaging.translatum@tum.de](mailto:bioimaging.translatum@tum.de)

alterations of cellular function by the introduction of the label<sup>6–8</sup>. Moreover, development of labels requires laborious validation and may nevertheless lead to insufficient performance, for example, in labeling Chol in living cells<sup>8</sup>.

These challenges have steered attention to label-free techniques for lipid sensing. Third harmonic generation<sup>9</sup> and optical<sup>10</sup> or optoacoustic methods<sup>11–18</sup> in the 900–1,800 nm spectral region can sense lipids without the use of labels but do not separate lipid classes. Mid-infrared (mid-IR) spectroscopy, at the 2,900–2,800 cm<sup>-1</sup> range, also reveals C–H single-bond stretching modes representative of lipids<sup>19</sup> but was not found sufficient to differentiate lipid species. Label-free detection of intracellular unsaturated and saturated lipid droplets has been proven possible with stimulated Raman scattering microscopy in the high wavenumber (3,050–2,800 cm<sup>-1</sup>) and fingerprint region (1,780–1,200 cm<sup>-1</sup>) in bacteria and cancer cells<sup>20,21</sup>. Coherent anti-Stokes Raman scattering (CARS) improves Raman detection sensitivity of lipid droplets in living adipocytes<sup>22</sup>. However, applied to the single-bond C–H stretching band (3,100–2,800 cm<sup>-1</sup>), common in a multitude of molecules including carbohydrates, nucleic acids and the hydrocarbon chain of the majority of lipids, CARS attains reduced specificity to different lipid classes owing to signal crosstalk<sup>23</sup>. Integration of hyperspectral stimulated Raman scattering with *k*-means clustering and multivariate curve resolution has been proposed to improve the specificity but is also challenged by low sensitivity<sup>24</sup>. Indeed, so far, in vivo detection of different lipid classes, such as Chol, has only been possible when hyperspectral stimulated Raman scattering was combined with isotopic labeling or applying computational unmixing methods to resolve the spectral overlap in the C–H stretching region<sup>25,26</sup>.

In the quest for label-free sensing of lipid species in living cells, we investigated optoacoustic detection in the mid-IR fingerprint region. Fingerprint bands reveal fine biomolecular content but exhibit weak Raman scattering cross-sections<sup>25</sup>. Conversely, using photon absorption rather than scattering, mid-IR cross-sections are stronger than Raman<sup>19</sup>, potentially leading to higher sensitivity and signal-to-noise ratio. To perform this investigation, we introduce hyperspectral fingerprint optoacoustic microscopy (hyFOPM), operating at 1,730–900 cm<sup>-1</sup>, aimed at sensing the specific single-bond vibrational modes of lipids. The system also allows scanning of the single-bond C–H stretching region (2,932–2,770 cm<sup>-1</sup>), for reference purposes.

Here, we show hyFOPM specificity to different lipid species with controlled phantoms and with three-dimensional (3D) synthetic giant unilamellar vesicles (GUVs), the latter serving as models for the cell membrane. In particular, we unmixed lipid contributions in GUVs composed of different mixes of Chol, SM and unsaturated phosphatidylcholine (1,2-dioleoyl-*sn*-glycero-3-phosphocholine, DOPC). Chol and SM were selected because they play a major role in several cellular functions and have a different chemical structure, whereby DOPC was selected owing to its chemical structural similarity to SM, as a control molecule. Results were contrasted to attenuated total reflectance–Fourier transform infrared (ATR–FTIR) measurements. Then, applied to live cell imaging, hyFOPM followed and separated the dynamics of SM and Chol in human embryonic kidney (HEK) cells and lung adenocarcinoma cells. We discuss the implications of label-free separation of lipids in the study of cancer, neurodegenerative, cardiovascular and other diseases and the opportunities that hyFOPM detection opens in the study of metabolic processes<sup>27</sup>.

## Results

### Lipid phantoms

HyFOPM was developed (Extended Data Fig. 1) and applied to measuring a two-dimensional (2D) lipid phantom (Fig. 1a–c), composed of a four-well carbon tape grid, each well containing Chol, DOPC, SM and water (Fig. 1d–f and Supplementary Video 1). HyFOPM spectra were acquired over the 1,730–900 cm<sup>-1</sup> (fingerprint) and


2,932–2,770 cm<sup>-1</sup> bands, with 2 cm<sup>-1</sup> spectral resolution over 7 min, and showed good correspondence with ATR–FTIR spectra acquired from the same samples (Fig. 1a–c) and to mid-IR vibrational assignments from literature<sup>28–31</sup>. The Chol chemical structure with its four sterol rings differs substantially from SM, and these dissimilarities are reflected on the spectral signatures resolved, for example, the strong 1,056 cm<sup>-1</sup> peak ascribed to the deformation mode of the sterol rings structure<sup>29</sup> (Fig. 1a). Conversely, both DOPC and SM contain fatty acid chains and a polar head group with phosphate and choline, yielding similar spectra in the single-bond C–H stretching region but different spectral features in the fingerprint region. DOPC uniquely shows a peak at 1,731 cm<sup>-1</sup> typical of the C=O stretching mode of ester groups (Fig. 1b), while SM is characterized by three peaks (at 1,645, 1,555 and 1,464 cm<sup>-1</sup>), assigned to the amide bond vibrations (amide I and II), that are absent from the DOPC spectrum, and to the fatty acid CH<sub>2</sub> bending (Fig. 1c). These spectral differences in the fingerprint region between SM and DOPC were validated by reproducibility studies (Extended Data Fig. 2).

To examine the correspondence of the spectra collected to the mid-IR vibrational assignments in literature, we analyzed hyFOPM spectra taken from the 2D phantoms at 22 wavenumbers (Table 1) spanning the C–H stretching and the fingerprint spectral region (Supplementary Video 1). The wavenumbers were selected to indicate key features (for example, peaks) seen on the SM, Chol and DOPC spectra in Fig. 1a–c.

In a next step, we aimed to investigate the identification and separation of the phantom lipids, water and carbon tape contributions from each other. Linear unmixing was performed at (1) the 22 wavenumbers in Table 1, (2) only 7 wavenumbers in the C–H stretching region and (3) only 15 wavenumbers in the fingerprint spectral region. In Fig. 1d–f, we show the unmixed hyFOPM images at the (3) fingerprint region, whereby Chol is highlighted in cyan (Fig. 1d), DOPC in yellow (Fig. 1e) and SM in magenta (Fig. 1f). For comparison, we report the results of linear unmixing applied respectively to the images of (2) only the C–H stretching region and to (1) all the 22 wavenumbers hyFOPM images (Extended Data Fig. 3a–c, e–g). In all three cases analyzed, linear unmixing separated Chol, DOPC and SM; however, not with the same accuracy. Crosstalk was characterized by tracing profiles along the wells of the unmixed images and plotting the mean intensity of the line profile as a pie chart. The SM was clearly distinguishable from other lipids in all the three cases (1), (2) and (3) (Fig. 1g and Extended Data Fig. 3d, h), Chol was well separated only in case (1) and (3) (Fig. 1g and Extended Data Fig. 3d, h). DOPC exhibited high crosstalk in all the three cases (Fig. 1g and Extended Data Fig. 3d, h). Overall, linear unmixing in the fingerprint region only (3) yielded the lowest crosstalk (Fig. 1g) compared with (1) or (2).

To improve spectral separation, we applied a linear discriminant analysis (LDA) to the three data sets (1, 2 and 3). LDA projection (Fig. 1h and Extended Data Fig. 4a, b) showed a clear class separation between the three lipids in all (1, 2 and 3) cases. The performance of the LDA classification was evaluated with confusion matrixes, which indicated an average comparable accuracy of 96% in classifying the lipids when the (3) fingerprint or only (2) the C–H stretching images were used (Extended Data Fig. 4d, e) and an average accuracy of 97% when using the entire dataset of images (Extended Data Fig. 4f). We also applied LDA to a subset of fingerprint wavenumbers (1,731, 1,645, 1,555, 1,464, 1,375 and 1,056 cm<sup>-1</sup>), selected by considering the strong absorption peaks of the three lipids in Fig. 1a–c. LDA projection of hyFOPM pixels acquired at selected wavenumbers showed distinguishable grouping between the three lipids (Extended Data Fig. 4c), with confusion matrixes revealed an accurate labeling for SM and Chol and a mislabeling of 20% for DOPC (Extended Data Fig. 4g), owing to the similarity with SM.

To corroborate the hyFOPM ability to distinguish between lipids with similar vibrational modes and address potential cross-reactivity, we imaged a 2D phantom comprising DOPC, dioleoyl



**Fig. 1 | Imaging and spectroscopy of a 2D lipid phantom by hyFOPM.**

**a–c**, Comparison of mid-IR absorption hyperspectra of dried Chol (**a**), DOPC (**b**) and SM [SM 18:0] (**c**) measured by hyFOPM and by ATR-FTIR spectroscopy. Yellow and pink shading highlights significant spectral differences between DOPC and Chol. **d–f**, Contrast separation between Chol (**d**), DOPC (**e**) and SM (**f**) resulting from linear unmixing of the 2D phantom spectral images in the

fingerprint region. **g**, Pie charts illustrating the crosstalk between unmixed images in **d** to **f**, presented as the mean value of the line profile drawn in **d** to **f**. Chol, DOPC and SM exhibited crosstalk levels of 0%, 23% and 0%, respectively. **h**, LDA projection of the hyFOPM pixels acquired in the fingerprint region. Scale bar, 1 mm.  $N = 3$ . NOptA, normalized optoacoustic.

phosphatidylethanolamine (DOPE) and sphingosine-1-phosphate (S1P), which have similar absorption spectra (Extended Data Fig. 5a). The phantom was analyzed using linear unmixing (Extended Data Fig. 5b–g) and LDA (Extended Data Fig. 6) for the 1, 2 and 3 data-grouping cases.

## GUVs

We used three types of GUVs at different Chol, SM and DOPC mixes to create biomimetic models of the plasma membrane (Fig. 2a). The ternary phase diagram (Fig. 2h) illustrates the assumed lipid formulation of

**Table 1 | Mid-IR optoacoustic spectral bands with their relative mid-IR vibrational assignments**

Frequencies (wavenumber in $\text{cm}^{-1}$ )	Type of vibrations and assignment	Comment
2,932	$\nu_{\text{as}} \text{CH}_2$ , $\nu_{\text{as}} \text{CH}_3$	Chol
2,923	$\nu_{\text{as}} \text{CH}_2$ of acyl chain	DOPC
2,916	$\nu_{\text{as}} \text{CH}_2$	SM
2,900	$\nu_s \text{CH}_2$	Chol
2,866	$\nu_s \text{CH}_2$	Chol
2,852	$\nu_s \text{CH}_2$ of acyl chain	DOPC-SM
2,848	$\nu_s \text{CH}_2$ and $\text{CH}_3$	Chol
1,731	$\nu \text{C}=\text{O}$ ester group	DOPC
1,645	$\text{C}=\text{O}$ amide I	SM
1,555	$\delta \text{N}-\text{H}$ , $\nu \text{C}-\text{N}$ amide II	SM
1,464	$\alpha \text{CH}_2$ acyl chain	All
1,375	$\beta_s \text{CH}_3$	All
1,327	$\pi \text{CH}_2$	Chol
1,234	$\nu_{\text{as}} \text{PO}_2^-$	DOPC-SM
1,174	$\nu \text{C}-\text{O}$ , $\nu_s \text{C}-\text{C}-\text{O}$	DOPC
1,164	$\nu \text{C}-\text{O}$ , $\nu_s \text{C}-\text{C}-\text{O}$	SM
1,087	$\nu_s \text{PO}_2^-$	DOPC-SM
1,064	$\nu_{\text{as}} \text{C}-\text{C}-\text{O}$ , $\nu \text{C}-\text{O}-\text{H}$	DOPC-SM
1,056	$\delta \text{C}-\text{H}$ ring	Chol
1,023	$\beta \text{C}-\text{H}$ in plane	Chol
964	$\nu_{\text{as}} \text{N}(\text{CH}_3)_3$ , $\beta \text{C}=\text{C}$	DOPC-SM
958	$\beta =\text{C}-\text{H}$	Chol

Data are from ref. 29.  $\alpha$ , scissoring;  $\beta$ , bending;  $\delta$ , deformation;  $\nu$ , stretching;  $\pi$ , wagging;  $\rho$ , rocking;  $\tau$ , twisting (s, symmetric; as, asymmetric).

the three GUV models examined, each represented by a circular area in the pyramid. The first model (Fig. 2b) contained a 1:1 mixture of SM and Chol, where the saturated acyl chains of SM and the rigid Chol molecules alternate forming a densely packed and ordered membrane (GUV 1). The second model (Fig. 2c) comprised DOPC, SM and Chol at a 2:2:1 molar ratio, a combination that creates tightly packed liquid ordered microdomains of SM and Chol, co-existing with a liquid disordered phase composed of DOPC (GUV 2). This type of membrane, where liquid ordered and liquid disordered phases coexist, simulates the plasma membrane of cells. Lastly, the third model (Fig. 2d) consists only of DOPC, which creates a purely fluid and disordered membrane (GUV 3).

HyFOPM images of the three GUVs, showing the C-H vibrations of lipid contrast at  $2,852 \text{ cm}^{-1}$ , were corroborated by fluorescent images (Fig. 2b-d), using Nile red lipid staining. Although of lower resolution, due to the longer wavelengths used, hyFOPM images showed accurate anatomical correspondence with the fluorescent images. The GUV 1 contrast-to-noise ratio (CNR of 44; Fig. 2b) was  $\sim 3.1$  times higher than the CNR of GUVs 2 and 3 (Fig. 2c,d, CNR of 14 and 15, respectively).

The higher CNR of GUV 1 may be explained by the higher local lipid concentration found in efficiently packed membranes compared with disordered ones. However, the presence of small SM:Chol domains did not greatly affect the local lipid concentration of GUV 2, which had a similar CNR of GUV 3.

GUV spectra at the single-bond C-H stretching and the fingerprint regions were also acquired at different spatial locations on the GUV surface, and from different vesicles, with a spectral resolution of  $4 \text{ cm}^{-1}$  (Fig. 2e-g). The GUV 1 spectrum (Fig. 2e) unveiled contributions from the amide I-II and  $\text{CH}_2$  fatty acid chain SM peaks (at 1,645, 1,555 and  $1,464 \text{ cm}^{-1}$ ; Fig. 1c) and the sterol ring bending peak of Chol

(at  $1,056 \text{ cm}^{-1}$ ; Fig. 1a). The GUV 1 spectrum is plotted next to the SM and Chol spectra (Extended Data Fig. 7a). The GUV 2 spectrum (Fig. 2f) exhibited peaks at 1,645, 1,555 and  $1,464 \text{ cm}^{-1}$ , consistent with Fig. 1c, and a peak at  $1,056 \text{ cm}^{-1}$  representative of the Chol's sterol ring (Fig. 1a). The DOPC presence gives rise to the shoulder detectable at  $1,731 \text{ cm}^{-1}$ , as seen for DOPC (Fig. 1b). The spectral correlation between the GUV 2 spectrum and the spectra of the three lipids (Extended Data Fig. 7b) demonstrates that the peak at  $1,000 \text{ cm}^{-1}$  can be attributed to the presence of sucrose encapsulated inside the GUVs (Extended Data Fig. 7d). The DOPC-only GUV 3 (Fig. 2g) revealed an absorption spectrum similar to the one observed from the DOPC liquid solution (Fig. 1b and Extended Data Fig. 7c).


Linear unmixing of the GUV spectra examined the spectral variability of the three GUV types and the intervariability within the same GUV type due to variations in GUV production. We performed spectral measurements on ten different vesicles from each GUV type (Extended Data Fig. 8a-c) that are rendered as a cloud of dots on the ternary plot of Fig. 2i and depict the actual relative concentration of each lipid component in the GUV, over the targeted concentration (Fig. 2h). The GUV 1 cloud (pink) lies in the middle of the edge between Chol and SM, indicating a binary mixture between these two endmembers. The GUV 2 cloud (blue) appears at the center of the plot, suggesting the presence of all three lipids, while the GUV 3 cloud (green) is located near the DOPC vertex. To validate that the observed variability is due to actual variations in GUV lipid composition, we performed spectra reproducibility measurements, at different spatial points within the same GUV (Extended Data Fig. 8d-f), which demonstrated a markedly lower variation than spectra acquired from different GUVs (Extended Data Fig. 8a-c). This finding points to hyFOPM as a potent tool for characterizing the actual lipid composition of GUVs, thus enhancing the accuracy of GUV research.

### Live cells

We examined hyFOPM lipid detection in living cells, by resolving SM in 50 human lung adenocarcinoma cancer cells (A549), upon exposure to 2-hydroxyoleic acid (2-OHOA), an antitumor compound<sup>32</sup>. HyFOPM's spectra were acquired with  $2 \text{ cm}^{-1}$  spectral resolution before and after cell treatment with  $200 \mu\text{M}$  of 2-OHOA in the SM fingerprint region ( $1,600-1,400 \text{ cm}^{-1}$ ) and revealed the expected increase in SM-related peaks (for example,  $1,464 \text{ cm}^{-1}$ ) after treatment (Fig. 3a,b). Violin plots exhibited an increase in the area under the curve (AUC) at  $1,464 \text{ cm}^{-1}$  by 117%, after 72 h of exposure to 2-OHOA and two cell distributions, that is, cells enriched in SM and not (Fig. 3c). For comparison, we also investigated the spectral content of 50 A549 cells maintained in culture for 72 h without 2-OHOA stimulation (Fig. 3d,e), demonstrating an AUC increase of only 23% (Fig. 3f).


With the  $1,464 \text{ cm}^{-1}$  peak confirmed for SM in phantoms, GUVs and living cells, we repeated the hyFOPM measurement in 3,000 A549 cells using only four selected wavenumbers:  $2,852 \text{ cm}^{-1}$  (total C-H lipid contrast),  $1,540 \text{ cm}^{-1}$  (amide II protein contrast),  $1,464 \text{ cm}^{-1}$  (SM contrast) and  $1,048 \text{ cm}^{-1}$  (Chol contrast), to examine selectivity with a small number of spectral measurements (Fig. 3g and Extended Data Fig. 9a). The measurements confirmed the previous observations, with 2-OHOA-stimulated A549 cells showing an increase in SM (blue) in Fig. 3g,h, observed at three different time points (time 0, 48 and 72 h after 2-OHOA exposure) but not in Chol (Fig. 3i, red). The SM increase as a function of time was also visible in the total lipid response ( $2,852 \text{ cm}^{-1}$ ), whereby the protein contrast increased slightly (Extended Data Fig. 9b,c).

In a second experiment, HEK cells (HEK293) were incubated with methyl- $\beta$ -cyclodextrins (M $\beta$ CD) complexed with Chol, to increase their membrane Chol content. M $\beta$ CDs constituted a cavity that can carry hydrophobic molecules such as Chol; Chol is then delivered to the cell membrane<sup>33</sup>. HyFOPM's spectra of 50 HEK cells before (T0) and after incubation (T16) demonstrated a prominent change at  $1,048 \text{ cm}^{-1}$



**Fig. 2 | Lipid imaging and spectroscopy of GUVs by hyFOPM. a**, Schematic models of GUVs with the corresponding lipid chemical structures drawn using ChemDraw Software. **b–d**, Left: hyFOPM images of GUV 1 (**b**), GUV 2 (**c**) and GUV 3 (**d**). Right: the corresponding fluorescent images. Scanning time for the acquisition of the hyFOPM images was 6 min. Scale bar, 25  $\mu$ m,  $N = 3$ . **e–g**, HyFOPM spectra of GUVs in **b** to **d**.  $N = 75$ . **h**, Ternary phase diagram of DOPC [18:1( $\Delta$ 9-Cis) PC], brain *N*-stearoyl-*D*-erythro-sphingosylphosphorylcholine [18:0 SM (d18:1/18:0)] and Chol >98% concentrations in GUVs. The vertices of

the triangle represent pure components, while the edges are binary mixtures. The pink circular area corresponds to the molar ratio of GUV 1 composed by SM:Chol (1:1, molar ratio), the blue circular area corresponds to the molar ratio of GUV 2 composed by DOPC:SM:Chol (2:2:1, molar ratio), while the green circular area corresponds to GUV 3 composed by only DOPC. **i**, Ternary phase diagram obtained from linear unmixing of the spectra in **e** to **g**. The position of the dots corresponds to the contribution of the three different lipids.  $N = 10$ . OptA, optoacoustic.



**Fig. 3 | Imaging and spectroscopy of A549 SM-enriched cells upon 2-OHOA therapy.** **a,d**, Raw spectra of SM-enriched A549 cells (**a**) and control (**d**) at different time points (T0, 0 h; T48, 48 h; T72, 72 h). **b,e**, Normalized and medium subtracted spectra of SM-enriched A549 cells (**b**) and control (**e**). Spectra were acquired in 50 cells. Data are presented as mean values  $\pm$  s.d. **c,f**, Violin plots showing the kernel density of the AUC values for SM-enriched (**c**) and control (**f**) A549 cells at different time points. Box plot minima and maxima inside the violin plots indicate the interquartile range, the white circles indicate the mean values and the whiskers indicate the s.d. (coefficient of 1). Outliers are shown as individual points. \*\*\* $P < 0.0001$  (**c**) and  $P = 4.18 \times 10^{-13}$  (**f**) from a two-sided paired

$t$ -test.  $N = 3$ . **g**, HyFOPM micrographs of SM-enriched cells at different time points (T0, 0 h; T48, 48 h; T72, 72 h). Overlay maps are obtained from SM (1,464 cm<sup>-1</sup>) and Chol contrast (1,048 cm<sup>-1</sup>). **h,i**, Box plots representing the OptA contrast of the micrographs in **g**: the SM contrast (1,464 cm<sup>-1</sup>) (**h**) and the Chol contrast (1,048 cm<sup>-1</sup>) (**i**) for 2-OHOA-stimulated A549 cells. Box plots indicate the standard error of the mean (s.e.m.; coefficient of 1; box limits), the white circles indicate the mean values, while the centered lines indicate the median values, and the whiskers indicate the s.d. (coefficient of 1). Outliers are shown as individual points. \*\*\* $P < 0.0001$  (**h**) and  $P = 9.59 \times 10^{-4}$  (**i**) from a two-sided paired  $t$ -test. Scale bar, 300 μm,  $N = 3$ . OptA, optoacoustic; NOptA, normalized optoacoustic.


(Fig. 4a). There is an 8 cm<sup>-1</sup> shift, between the 1,048 cm<sup>-1</sup> and the 1,056 cm<sup>-1</sup> peak where Chol was observed in the phantom (Fig. 1a) and in the GU (Fig. 2e,f) measurement, due to the interaction of Chol with MβCD, resulting in an MβCD–Chol complex (Extended Data Fig. 10a,b). Violin plots of Chol demonstrated an AUC increase of 161% compared with the pre-exposure values (Fig. 4b), demonstrating a strong signal enhancement.

Chol detection from ~3,000 HEK cells was performed at five selected wavenumbers: 2,852 cm<sup>-1</sup> (total C–H lipid contrast), 1,540 cm<sup>-1</sup> (amide II protein contrast), 1,375 and 1,048 cm<sup>-1</sup> (Chol contrast), and 1,464 cm<sup>-1</sup> (SM contrast), confirming the Chol increase after 16 h incubation at 1,048 and 1,375 cm<sup>-1</sup> (Fig. 4d and Extended Data Fig. 10d) and at

the total lipid hyFOPM contrast at 2,852 cm<sup>-1</sup> (Extended Data Fig. 10e). By contrast, the protein hyFOPM signal at 1,540 cm<sup>-1</sup> (amide II) did not show a considerable increase after incubation (Extended Data Fig. 10f), and the 1,464 cm<sup>-1</sup> wavenumber (SM contrast) showcased a slight decrease after incubation (Fig. 4e). This SM decrease can be explained by the known MβCD–Chol complex behavior to donate Chol while extracting other lipids from the plasma membrane<sup>33,34</sup>.

## Discussion

The ability to identify specific lipid classes in GUVs and in cells is essential to a broad range of applications, from understanding dynamic relationships in lipid metabolism to studying a variety of health conditions.



**Fig. 4 | Imaging and spectroscopy of HEK cells after Chol loading via incubation with M $\beta$ CD complexed with Chol.** **a**, Differential spectra between 50 Chol-enriched and unenriched HEK cells. Data are presented as mean values  $\pm$  s.d. For comparison, M $\beta$ CD–Chol complex spectrum acquired with ATR–FTIR spectroscopy is shown in black. Chol-enriched HEK cells showed a peak at 1,048  $\text{cm}^{-1}$ , corresponding to the absorption peak of the M $\beta$ CD–Chol complex. **b**, Violin plots showing the kernel density of the AUC of the peak at 1,048  $\text{cm}^{-1}$  before (TO) and 16 h (T16) after exposure to the M $\beta$ CD–Chol complex. Box plot minima and maxima inside the violin plots indicate the interquartile range, the white circles indicate the mean values and the whiskers indicate the s.d. (coefficient of 1). Outliers are shown as individual points.  $***P = 1.46 \times 10^{-28}$  from a two-sided paired  $t$ -test.  $N = 3$ . **c**, HyFOPM micrographs of HEK cells before (TO) and after treatment (T16) with M $\beta$ CD–Chol complexes. Overlay maps are obtained from Chol (1,048  $\text{cm}^{-1}$ ) and SM contrast (1,464  $\text{cm}^{-1}$ ). **d, e**, Box plots representing the OptA contrast of the micrographs in **c**: the Chol contrast (1,048  $\text{cm}^{-1}$ ) (**d**) and the SM contrast (1,464  $\text{cm}^{-1}$ ) (**e**) for M $\beta$ CD-treated HEK cells at time 0 h (TO) and 16 h (T16). Box plots indicate the s.e.m. (coefficient of 1; box limits), the white circles indicate the mean values, while the centered lines the median values, and the whiskers indicate the s.d. (coefficient of 1). Outliers are shown as individual points.  $***P = 6.19 \times 10^{-12}$  (**d**) and  $P = 5.48 \times 10^{-8}$  (**e**) from a two-sided paired  $t$ -test. Scale bar, 300  $\mu\text{m}$ ,  $N = 3$ . OptA, optoacoustic; NOptA, normalized optoacoustic.

Observation of SM and Chol, in particular, can enhance research abilities associated with a broad spectrum of diseases, owing the implication of these two lipids in atherosclerosis and stroke<sup>35</sup>, cognitive and neurodegenerative diseases<sup>36</sup> or cancer<sup>37</sup>. We showed that the positive contrast of mid-IR optoacoustic detection and hyperspectral illumination enabled label-free detection of lipids in living cells, moving away from the use of fluorescence or isotope labels. We further found that the spectral specificity achieved in the fingerprint region (1,739–900  $\text{cm}^{-1}$ ) was better than in the C–H stretching region (2,932–2,770  $\text{cm}^{-1}$ ).

Label-free hyFOPM avoids the costly and lengthy development of specific labels and is not challenged by label delivery efficiency, selectivity and possible alteration of cellular function. By contrast, lipid selectivity is achieved by tuning the hyFOPM operation to the

spectral signatures of the lipids of interest, which can be dynamically adapted to the requirements of the investigation performed. Detection characteristics in this case relate to the ability to differentiate the spectrum of the lipid of interest within the collected spectrum, which contains contributions from spectra of other background molecules. While established spectral unmixing techniques were used herein to demonstrate that sufficient information for SM and Chol differentiation is contained in the spectra collected, in a deterministic manner, advanced spectral unmixing techniques, including the use of deep learning, can help to improve the sensitivity and specificity limits of the technique. Besides observing lipids in living cells, hyFOPM can also be used to characterize the composition of GUVs, improving quality control in their production, especially given that we found variations up to 40% in the lipid composition of GUVs over the assumed ones.

Mid-IR optoacoustic microscopy can sample at  $>150\text{-}\mu\text{m}$  depths in tissues<sup>19,38</sup>. Therefore, a next step is to apply hyFOPM at thicker specimens or in vivo. Other future developments should be aimed at hyFOPM acceleration, through optimal illumination and spectral processing techniques that allow spectral subsampling, and miniaturization, so that the method can be applied to bedside analysis or disseminated laboratory use associated with diagnosing lipid disorders<sup>39–42</sup>.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41592-026-03025-w>.

## References

- Vinson, L. J. Dietary lipids in health and disease. *Low Calor. Spec. Diet. Foods* **2019**, 23–37 (2018).
- Mizuno, H. et al. Fluorescent probes for superresolution imaging of lipid domains on the plasma membrane. *Chem. Sci.* **2**, 1548–1553 (2011).
- Yuan, Z. & Hansen, S. B. Cholesterol regulation of membrane proteins revealed by two-color super-resolution imaging. *Membranes* **13**, 250 (2023).
- Arumugam, S. et al. Ceramide structure dictates glycosphingolipid nanodomain assembly and function. *Nat. Commun.* **12**, 3675 (2021).
- Eggeling, C. et al. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. *Nature* **457**, 1159–1162 (2009).
- Lorzate, M. et al. Super-resolution microscopy using a bioorthogonal-based cholesterol probe provides unprecedented capabilities for imaging nanoscale lipid heterogeneity in living cells. *Small Methods* **5**, e2100430 (2021).
- Dean, K. M. & Palmer, A. E. Advances in fluorescence labeling strategies for dynamic cellular imaging. *Nat. Chem. Biol.* **10**, 512–523 (2014).
- Rakers, L. et al. Addressable cholesterol analogs for live imaging of cellular membranes. *Cell Chem. Biol.* **25**, 952–961 (2018).
- Débarre, D. et al. Imaging lipid bodies in cells and tissues using third-harmonic generation microscopy. *Nat. Methods* **3**, 47–53 (2006).
- Zhao, Y. et al. Shortwave-infrared meso-patterned imaging enables label-free mapping of tissue water and lipid content. *Nat. Commun.* **11**, 5355 (2020).
- Fasoula, N. A. et al. Non-invasive multispectral optoacoustic tomography resolves intrahepatic lipids in patients with hepatic steatosis. *Photoacoustics* **29**, 100454 (2023).
- Karlas, A. et al. Multispectral optoacoustic tomography of lipid and hemoglobin contrast in human carotid atherosclerosis. *Photoacoustics* **23**, 100283 (2021).

13. Fasoula, N. A. et al. Multicompartmental non-invasive sensing of postprandial lipemia in humans with multispectral optoacoustic tomography. *Mol. Metab.* **47**, 101184 (2021).
14. Karlas, A. et al. Optoacoustic biomarkers of lipids, hemorrhage and inflammation in carotid atherosclerosis. *Front. Cardiovasc. Med.* **10**, 1210032 (2023).
15. Buma, T., Farland, J. L. & Ferrari, M. R. Near-infrared multispectral photoacoustic microscopy using a graded-index fiber amplifier. *Photoacoustics* **4**, 83–90 (2016).
16. Buma, T., Conley, N. C. & Choi, S. W. Multispectral photoacoustic microscopy of lipids using a pulsed supercontinuum laser. *Biomed. Opt. Express* **9**, 276–288 (2018).
17. Ntziachristos, V. Addressing unmet clinical need with optoacoustic imaging. *Nat. Rev. Bioeng* **3**, 182–184 (2025).
18. Knieling, F., Lee, S. & Ntziachristos, V. A primer on current status and future opportunities of clinical optoacoustic imaging. *npj Imaging* **3**, 4 (2025).
19. Pleitez, M. A. et al. Label-free metabolic imaging by mid-infrared optoacoustic microscopy in living cells. *Nat. Biotechnol.* **38**, 293–296 (2020).
20. Li, J. et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. *Cell Stem Cell* **20**, 303–314 (2017).
21. Tague, N. et al. Longitudinal single-cell imaging of engineered strains with stimulated Raman scattering to characterize heterogeneity in fatty acid production. *Adv. Sci.* **10**, e2206519 (2023).
22. Fung, A. A. & Shi, L. Mammalian cell and tissue imaging using Raman and coherent Raman microscopy. *Wiley Interdiscip. Rev. Syst. Biol. Med.* **12**, e1501 (2020).
23. Fu, D. et al. In vivo metabolic fingerprinting of neutral lipids with hyperspectral stimulated Raman scattering microscopy. *J. Am. Chem. Soc.* **136**, 8820–8828 (2014).
24. Wang, P. et al. Imaging lipid metabolism in live *Caenorhabditis elegans* using fingerprint vibrations. *Angew. Chemie* **53**, 11787–11792 (2014).
25. Tan, Y., Lin, H. & Cheng, J. X. Profiling single cancer cell metabolism via high-content SRS imaging with chemical sparsity. *Sci. Adv.* **9**, eadg6061 (2023).
26. Zhang, W. et al. Multi-molecular hyperspectral PRM-SRS microscopy. *Nat. Commun.* **15**, 1599 (2024).
27. Slotte, J. P. Biological functions of sphingomyelins. *Prog. Lipid Res.* **52**, 424–437 (2013).
28. Portaccio, M., Faramarzi, B. & Lepore, M. Probing biochemical differences in lipid components of human cells by means of ATR-FTIR spectroscopy. *Biophysica* **3**, 524–538 (2023).
29. Gupta, U., Singh, V., Kumar, V. & Khajuria, Y. Spectroscopic studies of cholesterol: Fourier transform infra-red and vibrational frequency analysis. *Mater. Focus* **3**, 211–217 (2014).
30. Movasaghi, Z., Rehman, S. & Rehman, I. U. Fourier transform infrared (FTIR) spectroscopy of biological tissues. *Appl. Spectrosc. Rev.* **43**, 134–179 (2008).
31. Derenne, A., Vandersleyen, O. & Goormaghtigh, E. Lipid quantification method using FTIR spectroscopy applied on cancer cell extracts. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **1841**, 1200–1209 (2014).
32. Barceló-Coblijn, G. et al. Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. *Proc. Natl Acad. Sci. USA* **108**, 19569–19574 (2011).
33. Zidovetzki, R. & Levitan, I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. *Biochim. Biophys. Acta* **1768**, 1311–1324 (2007).
34. Giocondi, M. C., Milhiet, P. E., Dosset, P. & Le Grimellec, C. Use of cyclodextrin for AFM monitoring of model raft formation. *Biophys. J.* **86**, 861–869 (2004).
35. Lim, R. S. et al. Identification of cholesterol crystals in plaques of atherosclerotic mice using hyperspectral CARS imaging. *J. Lipid Res.* **52**, 2177–2186 (2011).
36. Carsana, E. V. et al. Massive accumulation of sphingomyelin affects the lysosomal and mitochondria compartments and promotes apoptosis in Niemann–Pick disease type A. *J. Mol. Neurosci.* **72**, 1482–1499 (2022).
37. Tallima, H., Azzazy, H. M. E. & El Ridi, R. Cell surface sphingomyelin: key role in cancer initiation, progression, and immune evasion. *Lipids Health Dis.* **20**, 150 (2021).
38. Uluç, N. et al. Non-invasive measurements of blood glucose levels by time-gating mid-infrared optoacoustic signals. *Nat. Metab.* **6**, 678–686 (2024).
39. Jiang, X. & Daniel, S. O. Advancing diagnosis and treatment of Niemann–Pick C disease through biomarker discovery. *Explor. Neuroprotective Ther.* **1**, 146–158 (2022).
40. Bajwa, H. & Azhar, W. Niemann–Pick disease. *StatPearls* <https://www.ncbi.nlm.nih.gov/books/NBK556129/> (2025).
41. Huang, B., Song, B. L. & Xu, C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. *Nat. Metab.* **2**, 132–141 (2020).
42. Li, R. Z. et al. The key role of sphingolipid metabolism in cancer: new therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance. *Front. Oncol.* **12**, 941643 (2022).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026

## Methods

### HyFOPM description

The hyFOPM (Extended Data Fig. 1) experimental setup comprised a custom-built microscope configured for hyperspectral mid-IR excitation and OptA detection. A quantum cascade laser (QCL; Mircat, Daylight solutions) served as the mid-IR source, tunable between 3.4 and 11.0  $\mu\text{m}$  (2,932–900  $\text{cm}^{-1}$ ) with a spectral linewidth of  $\leq 1 \text{ cm}^{-1}$  (full-width at half maximum). The QCL emitted 20 ns pulses at a repetition rate of 100 kHz. The mid-IR beam was directed via a set of gold-coated mirrors, expanded using a beam expander and then focused onto the sample plane by a reflective objective with a numerical aperture of 0.5 (36 $\times$ , Newport Corporation). The optical beam path was enclosed within a chamber continuously purged with  $\text{N}_2$  gas to eliminate interference from atmospheric  $\text{CO}_2$  and water vapor. Optical reference was provided by a mercury–cadmium–tellurium detector (Daylight Solutions), whose alignment with the QCL beam was facilitated with a visible laser pointer.

Samples were positioned on custom-made ZnSe (Edmund Optics) or ZnS (Crystal GmbH) dishes, which were placed on customized sample holders affixed to a motorized XYZ stage (Prior Scientific). Mid-IR absorption maps of samples were obtained using OptA signals detected by scanning a 25 MHz central frequency piezoelectric ultrasound transducer (Imasonic) immersed in coupling medium (deionized water or cell culture medium) along the focal plane. The motorized stage is capable of scanning up to a field of view (FOV) of 52  $\text{mm}^2$  and a maximum velocity of 20  $\text{mm/s}$ . The focused ultrasound transducer and the reflective objective are coaxially aligned to share the same focal plane as the sample. The raw OptA signals were amplified with a 63 dB low-noise amplifier (Narda-MITEQ) and filtered by a 50 MHz low pass filter (Mini-circuits). OptA signals were recovered using a data acquisition system (DAQ, Gage Applied) with a sampling rate of 200 MS/s. The hyFOPM system was controlled using custom software implemented in Matlab. HyFOPM has a spatial resolution of 4.3  $\mu\text{m}$  and an axial resolution of 45.2  $\mu\text{m}$  at 2,850  $\text{cm}^{-1}$  that have been experimentally determined by measuring the point-spread-function of 1  $\mu\text{m}$  polystyrene beads at 2,850  $\text{cm}^{-1}$ .

### CNR

The CNR was calculated as follows:

$$\text{CNR} = |\text{OA}_S - \text{OA}_B| / \text{Noise}_{\text{pkpk}}$$

where  $\text{OA}_S$  and  $\text{OA}_B$  are the intensities of a point in the sample and one in the background, respectively, and  $\text{Noise}_{\text{pkpk}}$  is the peak-to-peak amplitude of the noise level.

### 2D lipid-solution phantom

DOPC [18:1( $\Delta^9$ -Cis) PC], brain *N*-stearoyl-D-erythro-sphingosylphosphorylcholine [18:0 SM (d18:1/18:0)], Chol >98%, DOPE and SIP solutions (Avanti Polar Lipids) were dissolved in a solution of  $\text{CHCl}_3$ :MeOH (2:1 v/v) and placed on wells using carbon tape as a spacer and reference. Micrographs of the 2D lipid phantom, covering a 10  $\text{mm} \times 10 \text{ mm}$  FOV with a 25  $\mu\text{m}$  step size, were acquired at selected wavenumbers every 25 min.

### Spectral unmixing and LDA

For spectral analysis of the 2D phantom, the hyFOPM images were preprocessed by normalizing the image intensity at each wavenumber by the mean intensity of the spectrally flat carbon tape, thus compensating for instability of the imaging system over time. Furthermore, each pixel of the hyFOPM image was normalized by its L1-norm along the wavenumber dimension. Spectral unmixing was then performed individually for each pixel of a hyFOPM image with a non-negative least squares solver, using pre-recorded hyFOPM spectra of the pure lipids, water and carbon tape as endmembers. The endmember spectra were

normalized by their L1-norm. An LDA model was fit to manually labeled subsections of the three lipid wells shown in Fig. 1d–f with  $50 \times 50$  pixels each. For the 2D projections shown in Fig. 1h and Extended Data Figs. 4 and 6, the LDA was given all pixels of the selected subsections for supervised dimensionality reduction. For the evaluation of the classification performance using different subsets of wavenumbers, shown as confusion matrixes in Extended Data Figs. 4 and 6, the LDA was trained and tested in a fivefold cross-validation scheme.

### PVA-assisted GUVs formation

The polyvinyl alcohol (PVA)-assisted method, as described in ref. 43, was adapted to prepare three types of GUVs with distinct lipid compositions, that is, (1) GUV 1, composed of SM and Chol in a 1:1 molar ratio; (2) GUV 2, containing DOPC, SM and Chol in a 2:2:1 molar ratio; and (3) GUV 3, consisting only of DOPC. All three lipid stock solutions were first prepared at a concentration of 1  $\text{mg/ml}$  in a ratio of 1:1  $\text{CHCl}_3$ :MeOH and then mixed in the specified ratios to form the three lipid compositions. Each lipid solution was added to a PVA-coated vial and heated to 50  $^\circ\text{C}$  to remove the solvents. The PVA coating was created by dissolving PVA fully hydrolyzed powder (Sigma-Aldrich) in 280 mM sucrose (Sigma-Aldrich) and heating it to 90  $^\circ\text{C}$  until completely dissolved, resulting into a 5% (w/v) PVA solution. A 200  $\mu\text{l}$  aliquot of the PVA solution was then transferred into a 5 ml glass vial and placed in a desiccator overnight, allowing the solution to vaporize and to create a uniform thin PVA coating. To induce GUV formation, 280 mM sucrose was added to the lipid–PVA mixture, followed by incubation at 37  $^\circ\text{C}$  for 20 min. Afterward, 300  $\mu\text{l}$  additional sucrose was added to suspend the GUVs. A 200  $\mu\text{l}$  aliquot of the GUV suspension was, finally, sedimented on the imaging dish using phosphate-buffered saline. The scanning time required for hyFOPM images of GUVs was 6 min.

### Cell culture

Accumulation of SM and Chol was performed respectively on a human adenocarcinoma alveolar basal epithelial cell line (A549, American Type Culture Collection (ATCC): CCL-185) and a HEK cell line (HEK293, ATCC: CRL-1573). A549 cells were cultured in Dulbecco's Modified Eagle Medium/Nutrient Mixture F12 (DMEM/F12, Gibco) supplemented with 10% fetal bovine serum (FBS, Merck,) and 1% penicillin–streptomycin (Sigma-Aldrich). HEK293 cells were cultured in Minimum Essential Medium (MEM, Gibco) supplemented with 10% FBS and 1% penicillin–streptomycin. Cells were grown in an incubator at 37  $^\circ\text{C}$ , 5%  $\text{CO}_2$  and 20%  $\text{O}_2$ . Accumulation of SM was induced via treatment with 200  $\mu\text{M}$  2-OHOA solution (Avanti Polar Lipids). Spectra and images of A549 treated cells were recorded at time 0 h, time 48 h and time 72 h (T0, T48 and T72). Accumulation of Chol was induced via treatment with 1  $\text{mM}$  M $\beta$ CD–Chol complex (Sigma-Aldrich). Spectra and images of HEK treated cells were recorded after 16 h of exposure to M $\beta$ CD–Chol complex.

### Analysis of spectra

For statistical elaboration, 50 spectra of A549 and HEK cells were acquired in the fingerprint skeletal range (from 1,600 to 1,400  $\text{cm}^{-1}$  for A549 cells, and from 1,070 to 900  $\text{cm}^{-1}$  for HEK cells). In both live cell experiments, spectra were preprocessed by removing the baseline offset by subtraction of the first spectral value, followed by normalization to the spectrum's final point. The corrected spectra were then interpolated along the spectral range using a spline function to ensure consistent sampling for all measurements. To minimize background or medium contribution, the corresponding background or medium-normalized spectrum was subtracted from the spectrum of the cells. Finally, spectra were normalized to their maximum intensity to facilitate comparison between samples. In the case of Chol accumulation, differential spectra between normalized spectra acquired at time 0 (T0) and spectra at time 16 h (T16) were calculated. The spectra shown in Figs. 3b,e and 4a correspond to mean values  $\pm$  standard deviation

(s.d.) values obtained from 50 different cells. Violin plots (Figs. 3c,f and 4b) were generated on the basis of AUC values for the band spanning 1,484–1,424  $\text{cm}^{-1}$  (Fig. 3b,e) and the band spanning 1,062–1,026  $\text{cm}^{-1}$  (Fig. 4a). Kernel density estimation was applied to visualize the data distribution. Each plot shows the probability density of the dataset, mirrored vertically, with embedded box plot elements (median and interquartile range) included. Matlab 2019 and OriginPro9 software were used for data analysis.

### Image processing

HyFOPM micrographs of A549 and HEK living cells with an FOV of 1.5 mm  $\times$  1.5 mm (pixel size of 5  $\mu\text{m}$ , 50 average) were acquired at different wavenumbers (2,852, 1,540, 1,464, 1,375 and 1,048  $\text{cm}^{-1}$ ), as shown in Figs. 3g and 4c and Extended Data Figs. 9a and 10c. The scanning time required for each micrograph was 15 min per wavenumber. The hyFOPM micrographs were analyzed using ImageJ software. First, micrographs were normalized by background/medium subtraction, and then the region of interest containing cells was segmented and the OptA intensity of the cells was extracted. The optoacoustic intensity extracted from the micrographs is shown in the form of box plots in Figs. 3h,i and 4d,e and Extended Data Figs. 9b,c and 10d–f.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

The data supporting the findings of this study are available upon reasonable request from the corresponding author because they are currently in use for other publications. Source data are provided with this paper.

### References

- Stein, H., Spindler, S., Bonakdar, N., Wang, C. & Sandoghdar, V. Production of isolated giant unilamellar vesicles under high salt concentrations. *Front. Physiol.* **8**, 63 (2017).

### Acknowledgements

The research leading to these results was supported by the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme under grant agreement no. 694968 (PREMSOT) and the European Union's Horizon Europe Research and Innovation Programme under grant agreement no. 101058111 (GLUMON), the Deutsche Forschungsgemeinschaft (DFG) as part of the CRC 1123 (Z1), the Gottfried Wilhelm Leibniz Prize 2013; NT 3/10-1 and 455422993 as part of the Research Unit FOR 5298 (iMAGO, subproject TP2, GZ: NT 3/32-1) to V.N. This project was supported by the Deutsche Forschungsgemeinschaft (DFG) as part of the Research Unit FOR 5298 (iMAGO, subproject TP3, GZ: PL825/3-1)

to M.A.P. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the paper. We thank S. Lee, E. Bonnin and R. Wilson for assisting with editing of the paper. We also thank M. Grzybek and Ü. Coskun from Center of Membrane Biochemistry and Lipid Research, University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden and German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany, for providing their expert input on lipids.

### Author contributions

F.G. performed all the imaging/spectroscopy experiments, processed the results, prepared figure panels and wrote the paper. A.P. performed the unmixing and linear discriminant analysis of the lipid phantom and helped with the spectra analysis. A.S. designed the study of the lipid phantom, giant unilamellar vesicles (GUV) and sphingomyelin accumulation. N.U. helped with the spectra analysis and the imaging system. S.G. prepared the GUV. C.B. performed the unmixing analysis of the GUVs. M.A.P. designed, built and characterized the hyFOP microscopy system. V.N. supervised the whole study and wrote the paper. All authors edited the paper.

### Funding

Open access funding provided by Technische Universität München.

### Competing interests

M.A.P. is a founder and equity owner of sThesis GmbH. V.N. is a founder and equity owner of Maurus OY, sThesis GmbH, Spear UG, Biosense Innovations P.C. and I3 Inc. V.N. and M.A.P. are inventors on a provisional patent application related to mid-IR optoacoustic microscopy (US-2020355604-A1, US Patent, 2018). The other authors declare no competing interests.

### Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41592-026-03025-w>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41592-026-03025-w>.

**Correspondence and requests for materials** should be addressed to Vasilis Ntziachristos.


**Peer review information** *Nature Methods* thanks Jianpeng Ao, Ji-Xin Cheng, Chengbo Liu and Claudio Vinegoni for their contribution to the peer review of this work. Primary Handling Editor: Nina Vogt, in collaboration with the *Nature Methods* team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).




**Extended Data Fig. 1 | A schematic overview of the hyperspectral fingerprint optoacoustic microscopy (hyFOPM) system.** The hyFOPM setup employs a tunable quantum cascade laser (QCL), operating over the spectral range of

3.4–11.0  $\mu\text{m}$ , to provide mid-infrared excitation suitable for hyperspectral imaging. Optoacoustic signal detection is achieved using a piezoelectric focused ultrasound (US) transducer with a central frequency of 25 MHz.




**Extended Data Fig. 2 | Bi-dimensional lipid phantom spectral reproducibility.** Mean ( $\mu$ ) and standard deviation ( $\sigma$ ) of spectra collected at different spatial location within the wells of the bi-dimensional lipid phantom. The coefficient of variation is expressed as  $\sigma/\mu$ . **a)** Mean and standard deviation of four cholesterol

(Chol) spectra. **b)** Mean and standard deviation of ten 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) spectra. **c)** Mean and standard deviation of ten sphingomyelin (SM) spectra. NOptA: Normalized Optoacoustic.




**Extended Data Fig. 3 | Linear unmixing and crosstalk pie charts. a-c)** Lipids' maps resulted from linear unmixing of hyFOPM images acquired in the CH-stretching region (cholesterol (Chol) in (a), phosphatidylcholine (DOPC) in (b), SM (SM) in (c)). **d)** Pie charts representing the cross talk of the three lipid channels in a-c. Chol, DOPC, SM exhibited crosstalk levels of -28%, 9%, and 3%,

respectively. **e-g)** Lipids' maps resulted from linear unmixing of hyFOPM images acquired in both the CH stretching and fingerprint region (Chol in (e), DOPC in (f) and SM in (g)). **h)** Pie charts representing the cross talk of the three lipid channels in e-g. Chol, DOPC, SM exhibited crosstalk levels of -1%, 25%, and 1%, respectively. Scale bar: 1 mm, N = 3.



**Extended Data Fig. 4 | Linear Discriminant Analysis (LDA) and confusion matrixes.** **a)** Scatter plot representing the LDA projections of hyperspectral fingerprint optoacoustic microscopy (hyFOPM) pixels obtained from images acquired in the CH stretching region. **b)** Scatter plot representing the LDA projections of hyFOPM pixels obtained from images acquired in the entire spectral region. **c)** Scatter plot representing the LDA of hyFOPM pixels obtained


from images at selected wavenumbers (1731, 1645, 1555, 1464, 1375, 1056  $\text{cm}^{-1}$ ). **(d-g)** Confusion matrixes extracted from the LDA analysis in Fig. 1g and (a-c). The confusion matrix in **(d)** originates from the LDA of the fingerprint pixels, the matrix in **(e)** from the LDA in the CH-stretching region, **(f)** from the LDA of all the spectral region, **(g)** from the LDA obtained for pixels at selected wavenumbers in the fingerprint region.



**Extended Data Fig. 5 | Linear unmixing and crosstalk pie charts for 2,3-dioleoyl-glycero-1-phosphocholine (DOPC), dioleoyl phosphatidylethanolamine (DOPE) and sphingosine-1-phosphate (S1P).**


**a**) Comparison of mid-infrared absorption spectra of DOPC, DOPE and S1P. **b**) Lipid maps from linear unmixing of hyperspectral fingerprint optoacoustic microscopy (hyFOPM) images acquired at thirty-seven wavenumbers covering the full spectral range (*i*). **c**) Pie charts representing the crosstalk of the three lipid channels calculated from **(b)**. DOPC, DOPE, and S1P exhibited crosstalk

levels of -13%, 4%, and 29%, respectively. **d**) Lipids maps from linear unmixing of HyFOPM images acquired only in the C-H stretching spectral region (*ii*). **e**) Pie charts representing the crosstalk of the three lipids channels calculated from **(d)**. DOPC, DOPE, and S1P exhibited crosstalk levels of -99%, 30%, and 12%, respectively. **f**) Lipids maps from linear unmixing of hyFOPM images acquired only in the fingerprint spectral region (*iii*). **g**) Pie charts representing the crosstalk of the three lipids channels calculated from **(f)**. DOPC, DOPE, and S1P exhibited crosstalk levels of -14%, 5%, and 36%, respectively. Scale bar: 1 mm.




**Extended Data Fig. 6 | Linear discriminant analysis (LDA) and confusion matrixes.** (a-c) Scatter plots representing LDA projections of hyperspectral fingerprint optoacoustic microscopy (hyFOPM) pixels obtained from images acquired at wavenumbers covering the (a) full spectral region, (b) only the

C-H stretching region, and (c) only the fingerprint region. Confusion matrixes originating from the LDA of (d) the full spectral region, (e) the C-H stretching region, (f) the fingerprint region.



**Extended Data Fig. 7 | Comparison between spectra of Giant Unilamellar Vesicles (GUVs) and GUVs' components.** (a) Comparison between the spectra of cholesterol (Chol), sphingomyelin (SM) and the spectrum of GUV 1 (1:1, SM:Chol). (b) Comparison between the spectra of Chol, SM, phosphatidylcholine (DOPC), and the spectrum of GUV 2 (2:2:1 DOPC:SM:Chol). (c) Comparison between the

spectrum of DOPC and the spectrum of GUV 3 (DOPC). (d) Spectra comparison of GUV 2 (dark blue) and sucrose (purple) used in GUV formation. The light blue line shows a GUV 2 example with minimal sucrose contribution. NOptA: Normalized Optoacoustic.




**Extended Data Fig. 8 | Giant unilamellar vesicles (GUV) spectra**

**reproducibility. a-c** Mean ( $\mu$ ) and standard deviation ( $\sigma$ ) of the ten spectral


points collected for each GUV model reported in Fig. 2i. **a**) Mean and standard deviation of ten points in GUV 1 (1:1 SM:Chol) **b**) Mean and standard deviation of ten points in GUV 2 (2:2:1 DOPC:SM:Chol). **c**) Mean and standard deviation of ten points in GUV 3 (DOPC). **d**) Mean and standard deviation of two points

located within the same GUV 1. **e**) Mean and standard deviation of three points located within the same GUV 2. **f**) Mean and standard deviation of five points located within the same GUV 3. The coefficient of variation is expressed as  $\sigma/\mu$ . DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine. Chol: cholesterol. SM: sphingomyelin. NOptA: Normalized Optoacoustic.



**Extended Data Fig. 9 | Spectral imaging of A549 sphingomyelin (SM) enriched cells upon 2-hydroxyoleic acid (2OHOA) treatment. a** Images monitoring at different time points (0 h = T0, 48 h = T48, and 72 h = T72) the accumulation of SM in A549 cells at 1540  $\text{cm}^{-1}$  (protein contrast), and 2852  $\text{cm}^{-1}$  (lipid contrast). Boxplots representing the optoacoustic (OptA) contrast of A549 cells in **(a)** at **(b)** 2852  $\text{cm}^{-1}$  (lipid contrast) and at **(c)** 1540  $\text{cm}^{-1}$  (protein contrast). Box plots

indicate the standard error (SE, coefficient =1; box limits), the white circles indicate the mean values, while the centered lines the median values, and the whiskers indicate the standard deviation (SD, coefficient =1). \*\*\* $p = 1.92 \times 10^{-241}$  (b) and  $1.21 \times 10^{-63}$  (c) from a two-sided paired t-test. N = 3. NOptA: Normalized Optoacoustic.



**Extended Data Fig. 10 | Spectral imaging of HEK cells after cholesterol (Chol) loading via incubation with methyl- $\beta$ -cyclodextrins (M $\beta$ CD) complexed with Chol. **a**) Comparison between the hyperspectral fingerprint optoacoustic microscopy (hyFOPM)'s spectra of a Chol liquid solution (green line) and of M $\beta$ CD - Chol complex (purple line). The Chol absorption peak shifts from 1056  $\text{cm}^{-1}$  to 1048  $\text{cm}^{-1}$  when Chol is complexed with cyclodextrins. **b**) Comparison between the Fourier transform infrared (FTIR) spectra of M $\beta$ CD complex with Chol (in red) and M $\beta$ CD without Chol (in blue). For comparison, the FTIR spectrum of a Chol liquid solution is plotted in black. **c**) HyFOPM images monitoring Chol loading in HEK cells at 1375  $\text{cm}^{-1}$  (Chol contrast), at 1540  $\text{cm}^{-1}$**

(protein contrast), and at 2852  $\text{cm}^{-1}$  (lipid contrast) before (T0) and after 16 hours (T16) of treatment with M $\beta$ CD-Chol. Boxplots representing the optoacoustic contrast of HEK cells in **(c)** at **(d)** 1375  $\text{cm}^{-1}$  (Chol contrast), at **(e)** 2852  $\text{cm}^{-1}$  (lipid contrast) and at **(f)** 1540  $\text{cm}^{-1}$  (protein contrast). Box plots indicate the standard error (SE, coefficient=1; box limits), the white circles indicate the mean values, while the centered lines the median values, and the whiskers indicate the standard deviation (SD, coefficient=1). Outliers are shown as individual points. \*\*\* $p = 2.24 \times 10^{-28}$  **(d)**,  $p = 3.16 \times 10^{-8}$  **(e)** and  $p = 0.0018$  **(f)** from a two-sided paired t-test.  $N = 3$ . OptA: Optoacoustic; NOptA: Normalized Optoacoustic.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	n/a
Reporting on race, ethnicity, or other socially relevant groupings	n/a
Population characteristics	n/a
Recruitment	n/a
Ethics oversight	n/a

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No sample-size calculation was performed. Sample size was always >10 samples. Results were replicated 3 times.
Data exclusions	No data was excluded from the analysis.
Replication	All the experiments presented here were successfully replicate independently at least three times.
Randomization	The samples for analysis were randomly selected from the available set, and any deviations or variations are detailed in the manuscript.
Blinding	GUVs, cells, and spectral points were randomly selected for analysis. Cross-reactivity studies involving phantoms and GUVs were performed in a blinded manner by the investigator.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

### Methods

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)	Human adenocarcinomic alveolar basal epithelial cell line (A549, ATCC: CCL-185) and a human embryonic kidney cell line
---------------------	--

Cell line source(s)	(HEK 293, ATCC: CRL-1573). Both cells line were provided from American Type Culture Collection (ATCC).
Authentication	None of the cell lines used were authenticated.
Mycoplasma contamination	All cell lines used were tested free from micoplasma.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	n/a

## Plants

---

Seed stocks	n/a
Novel plant genotypes	n/a
Authentication	n/a